Jakafi (ruxolitinib) — Highmark
Myelofibrosis
Initial criteria
- age ≥ 18 years
- diagnosis of myelofibrosis that is intermediate or high-risk
- if new start to therapy, baseline platelet count ≥ 50 x 10^9/L
Reauthorization criteria
- prescriber attests member has experienced a reduction in spleen size OR improvement in symptoms